Inventiva

September 12, 2017September 12, 2017

Inventiva Announces Further Collaboration with Boehringer Ingelheim to Develop IPF Therapies

Inventiva Pharma recently announced that Boehringer Ingelheim will extend a collaboration with the company to further advance potential treatments for fibrotic conditions including idiopathic pulmonary fibrosis (IPF). The collaboration began in May 2016 as a research and ... Read more

August 1, 2017August 1, 2017

Inventiva to Release Novel Data on Anti-fibrotic Product, IVA337, at Scleroderma Workshop

News

French pharmaceutical firm Inventiva will present novel data on its new anti-fibrotic product, IVA337, during the 15th International Workshop on Scleroderma Research, to be held Aug. 5-9 at the University of Pittsburgh. ... Read more

September 26, 2016September 26, 2016

Inventiva Receives €2.3 Million to Support YAP/TEAD Protein Research Program

Lung Cancer, News

Inventiva has been awarded two grants totaling €2.3 million ($2.58 million) to further its YAP/TEAD protein research program, which focuses on developing molecules with the potential to treat severe forms of lung, ... Read more

June 3, 2016June 6, 2016

Boehringer, Inventiva Form $190M IPF Research and Development Pact

Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim and Dijon, France-based Inventiva Pharma, a biopharma specializing in the development of innovative therapies for fibrosis, have announced the establishment of an idiopathic pulmonary fibrosis (IPF) research and development ... Read more

February 29, 2016March 16, 2016

Inventiva, Developer of Potential Therapy for Systemic Sclerosis, Awarded at 4th World Congress for Its Innovative Approach

Idiopathic Pulmonary Fibrosis, News, Scleroderma

Inventiva, a drug discovery company focused on the treatments of fibrotic, oncological, and rare diseases, announced that the organizing committee of the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, which ... Read more